Page 2 - Agtc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Applied Genetic Technologies (NASDAQ:AGTC – Get Rating) and TRACON Pharmaceuticals (NASDAQ:TCON – Get Rating) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends. Risk and Volatility Applied Genetic Technologies has a […]

StockNews.com started coverage on shares of Applied Genetic Technologies (NASDAQ:AGTC – Get Rating) in a research report issued to clients and investors on Thursday. The firm set a “sell” rating on the biotechnology company’s stock. Other equities analysts have also recently issued reports about the company. Roth Capital reissued a “buy” rating on shares of […]

Applied Genetic Technologies Co. (NASDAQ:AGTC – Get Rating) saw a large decrease in short interest in the month of February. As of February 28th, there was short interest totalling 1,590,000 shares, a decrease of 18.5% from the February 13th total of 1,950,000 shares. Approximately 4.2% of the company’s stock are short sold. Based on an […]

(3) LONDON (dpa-AFX) - Today's Daily Dose brings you news about Applied Genetic's Achromatopsia trial results; the deadlock in AstraZeneca vaccine supply in EU; partnership of Lilly, Vir Biotech and GlaxoSmithKline in fighting COVID-19; and ZymeWork's progress with ZW49 study. Read on. 1. Applied Genetic Throws Light on Achromatopsia Trials Applied Genetic Technologies Corp.'s (AGTC) phase I/II clinical trials evaluating AAV gene therapy product candidates in patients with achromatopsia caused by CNGB3 or CNGA3 mutations, dubbed ACHMB3 and ACHMA3 trials, have provided for the first time quan...